Drug Profile
Research programme: Poly(ADP-ribose) glycohydrolase inhibitors - Ideaya Biosciences
Alternative Names: PARG inhibitors - IDEAYA BiosciencesLatest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator IDEAYA Biosciences
- Class Antineoplastics; Small molecules
- Mechanism of Action Poly ADP ribose glycohydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for preclinical development in Solid-tumours in USA
- 01 Feb 2022 IDEAYA Biosciences enters into an exclusive option agreement with Cancer Research Institute and University of Manchester to cover broad class of PARG inhibitors, worldwide
- 10 Jan 2022 Ideaya Biosciences plans to file an IND application for Solid tumours, in the fourth quarter of 2022